Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating
Completed · Not applicable
Conditions studied: Antidepressant Induced Excessive Sweating
In brief
This study is based on the hypothesis that terazosin, a blocker of alpha-1 receptors, will be effective in reducing excessive sweating caused by antidepressant treatment, and will have minimal adverse effects.
Key facts
- Study ID
- NCT00237510
- Run by
- Thomas Jefferson University
- People needed
- 15
- Starts
- 2005-05-01
- Expected to finish
- 2007-05-01
- Last updated by the study team
- 2014-03-05
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Clinical diagnosis of a Depressive disorder (Diagnostic and Statistical Manual of Mental Disorders - IV-TR)
- Presence of excessive sweating by self-report
- The excessive sweating started after initiation of an antidepressant and, if treatment with the antidepressant was interrupted, did not persist for more than 4 weeks during that interruption
- Treatment with the antidepressant is deemed to be clinically necessary due to substantial benefit from this antidepressant, and failure to respond to or tolerate an alternative
- Excessive sweating has persisted for at least 4 weeks prior to baseline assessment
- The excessive sweating is rated by the patient as at least moderately bothersome.
- Episodes of excessive sweating occur at least twice a week for last 4 weeks
You may not qualify if…
- Presence of another known disease that could potentially cause excessive sweating
- Failure to respond to antiadrenergic (reducing activity of the sympathetic nervous system) treatment in the past
- Blood pressure less than 110 mm Hg systolic at the screening or baseline visits
- Orthostatic hypotension by history or on assessment at the screening or baseline visits (defined as a decrease of 10 mm Hg or greater after standing for 2 minutes).
- Current antihypertensive treatment
- History of significant cardiac disease, including coronary artery disease
- Current use of phosphodiesterase type 5 inhibitors: sildenafil (Viagra™), tadalafil (CialisTM), or vardenafil (LevitraTM)
- History of priapism (persistent and painful erection)
Where it is running
- Thomas Jefferson University Department of Psychiatry and Human Behavior — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.